Catégorie : Non classé

”State of the art on psychedelic research”, Iker Puente, 2018

”State of the art on psychedelic research" Iker Puente, PhD Integral European Conference (IEC) Siófok, Hungary, 27 May 2018   Psychedelic psychotherapy and research: history — 1st Phase: 1947-1970. First studies and beginning of research. — 2nd Phase: 1971-1989. Prohibition of studies and other uses. — 3nd Phase: 1990-2005. Beginning of new studies and research. — 4rd Phase: 2006-2016. Positive outcomes, change of social perception, blossoming of research, publications and positive media coverage. — Today: many studies in some of the most prestigious universities of the world: Johns Hopkins, Harvard, NYU, UCLA, Imperial College London… using MDMA, psilocybin, ketamine, LSD… (...)

Lire la suite

Opioid and healthcare service use in medical cannabis patients with chronic pain : a prospective study, Sharon Sznitman et al., 2021

Opioid and healthcare service use in medical cannabis patients with chronic pain: a prospective study Sharon Sznitman, Carolyn Mabouk, Zahi Said and Simon Vulfsons British Medical Journal, 2021. doi : 10.1136/bmjspcare-2020-002661 Abstract Background Various jurisdictions have legalised medical cannabis (MC) for use in chronic pain treatment. The objective of this study was to determine if the use of MC is related to a reduction in the use of prescription opioids and other prescription medications and healthcare services. Methods : A retrospective cohort study was conducted using the medical files of 68 Israeli patients with chronic pain using MC. Number of prescription medications filled and healthcare services [...]

Lire la suite

Use and Reported Helpfulness of Cannabinoids Among Primary Care Patients in Vermont, Nicole Wershoven et al., 2020

Use and Reported Helpfulness of Cannabinoids Among Primary Care Patients in Vermont Nicole Wershoven, Amanda G. Kennedy, and Charles D. MacLean Journal of Primary Care and Community Health, 2020, 11, 1-6. Doi : 10.1177/2150132720946954 Abstract Introduction : While cannabis has been medically legal in Vermont since 2004 and recreationally legal since 2018 there has been minimal published research regarding the use and practices in the adult population. This gap in understanding results in primary care providers having difficulty navigating conversations surrounding cannabinoid use. The purpose of this research was to identify current use and perceptions of cannabinoids, including Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in adult [...]

Lire la suite

High-Potency Cannabis Products Linked to Suicidality, Doug Brunk, Medscape.com, February 22, 2021

High-Potency Cannabis Products Linked to Suicidality Doug Brunk Medscape Medical News © 2021 WebMD, LLC February 22, 2021 Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. In the days since recreational sales of marijuana became legal in Colorado in January 2014, concerning trends have emerged among the state's young cannabis users. Dr Paula Riggs According to a report from the Rocky Mountain High Intensity Drug Trafficking Area, between 2014 and 2017, the number of suicides positive for marijuana increased 250% among those aged 10-19 years (from 4 to 14) and 22% among those aged 20 and older (from 118 to 144). "Other states are seeing something [...]

Lire la suite

Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis, Tibor M. Brunt et al., 2014

Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis Tibor M. Brunt, Marianne van Genugten, Kathrin Honer-Snoeken, Marco J. van de Velde, and Raymond J.M. Niesink Journal of Clinical Psychopharmacoly, 2014, 34, 344Y349 Doi : 10.1097/JCP.0000000000000129   Abstract : In The Netherlands, pharmaceutical-grade cultivated cannabis is distributed for medicinal purposes as commissioned by the Ministry of Health. Few studies have thus far described its therapeutic efficacy or subjective (adverse) effects in patients. The aims of this study are to assess the therapeutic satisfaction within a group of patients using prescribed pharmaceutical-grade cannabis and to compare the subjective effects among the available strains with special [...]

Lire la suite

Chapter 12 : Gnosis Potency : DMT Breakthroughs and Paragnosis, Graham St John, 2018

Chapter 12 : Gnosis Potency : DMT Breakthroughs and Paragnosis Graham St John in B. C. Labate, C. Cavnar (eds.), "Plant Medicines, Healing and Psychedelic Science", Springer International Publishing AG, part of Springer Nature 2018 doi : 10.1007/978-3-319-76720-8_12   Abstract DMT (N,N-dimethyltryptamine) is a powerful tryptamine that has experienced growing appeal in the last decade, independent from ayahuasca, the Amazonian visionary brew in which it is an integral ingredient. Investigating user reports available from literary and online sources, this chapter focuses on the gnosis potency associated with the DMT “breakthrough” experience. I explore the parameters of the tryptaminal state and, in particular, the extraordinary paragnosis associated with [...]

Lire la suite

Cannabis and the developing brain : Insights from behavior, Viviana Trezza et al., 2008

Cannabis and the developing brain : Insights from behavior Viviana Trezza, Vincenzo Cuomo, Louk J.M.J. Vanderschuren European Journal of Pharmacology, 2008, 585, 441-452. Doi : 10.1016/j.ejphar.2008.01.058   A B S T R A C T The isolation and identification, in 1964, of delta-9-tetrahydrocannabinol (THC), the primary psycho-active compound in cannabis, opened the door to a whole new field of medical research. The exploration of the therapeutic potential of THC and other natural and synthetic cannabinoid compounds was paralleled by the discovery of the endocannabinoid system, comprising cannabinoid receptors and their endogenous ligands, which offered exciting new insights into brain function. Besides its well-known involvement in specific [...]

Lire la suite

A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol : Δ9-Tetrahydrocannabiphorol, Cinzia Citti et al., 2019

A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol : Δ9-Tetrahydrocannabiphorol Cinzia Citti, Pasquale Linciano, Fabiana Russo, Livio Luongo, Monica Iannotta, Sabatino Maione, Aldo Laganà, Anna Laura Capriotti, Flavio Forni, Maria Angela Vandelli, Giuseppe Gigli & Giuseppe Cannazza Scientific Reports, 2019, 9, 20335 doi : 10.1038/s41598-019-56785-1 2   (-)-Trans-Δ9-tetrahydrocannabinol (Δ9-THC) is the main compound responsible for the intoxicant activity of Cannabis sativa L. The length of the side alkyl chain influences the biological activity of this cannabinoid. In particular, synthetic analogues of Δ9-THC with a longer side chain have shown cannabimimetic properties far higher than Δ9-THC itself. [...]

Lire la suite

Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats, Marcello Solinas et al., 2006

Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats Marcello Solinas, Zuzana Justinova, Steven R. Goldberg and Gianluigi Tanda Journal of Neurochemistry, 2006, 98, 408–419. doi:10.1111/j.1471-4159.2006.03880.x   Abstract Although endogenous cannabinoid systems have been implicated in the modulation of the rewarding effects of abused drugs and food, little is known about the direct effects of endogenous ligands for cannabinoid receptors on brain reward processes. Here we show for the first time that the intravenous administration of anandamide, an endogenous ligand for cannabinoid receptors, and its longer-lasting synthetic analog methanandamide, increase the extracellular dopamine [...]

Lire la suite

Cannabis thérapeutique : en avant vers l’expérimentation, Charles Delouche, Libération, 28 juin 2019

Cannabis thérapeutique : en avant vers l'expérimentation Par Charles Delouche, Libération,  — 28 juin 2019 à 18:36 Après un an d'études, le comité scientifique spécialisé a rendu son avis définitif sur la mise en place du cannabis thérapeutique en France. La balle est désormais dans le camp de l'Agence du médicament et de la Direction générale de la santé. Cannabis thérapeutique : en avant vers l'expérimentation Dévoilé avant même la fin du cycle des auditions le mercredi 19 juin, le projet final d’expérimentation du cannabis à visée thérapeutique a été dans l’ensemble favorablement accueilli par les associations de patients. Elles étaient [...]

Lire la suite